methamphetamine has been researched along with valproic acid in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hudson, JI; Pope, HG | 1 |
| Hanson, GR; Jensen, M; Johnson, M; White, HS | 1 |
| Geyer, MA; Kuczenski, R; Lohr, JB; Niculescu, AB; Ogden, CA; Paulus, MP; Rich, ME; Schork, NJ | 1 |
| Chen, SQ; Deng, YP; Han, R; Li, JX; Liang, JH | 1 |
| Abekawa, T; Ito, K; Koyama, T | 1 |
| Caprioli, A; Coccurello, R; Ghirardi, O; Virmani, A | 1 |
| Alesci, S; Bachmann, RF; Du, J; Li, X; Manji, HK; Wang, Y; Yuan, P; Zhou, R | 1 |
| Andersen, ML; da-Rosa, DD; Dal-Pizzol, F; Ferreira, CL; Lopes-Borges, J; Ornell, F; Quevedo, J; Steckert, AV; Valvassori, SS; Varela, RB | 1 |
| Andersen, ML; Bavaresco, DV; Feier, G; Morais, MO; Quevedo, J; Resende, WR; Scaini, G; Streck, EL; Valvassori, SS; Varela, RB | 1 |
| Bonci, A; Britt, JP; Cadet, JL; Chen, B; Jayanthi, S; Kourrich, S; Krasnova, IN; Ladenheim, B; McCoy, MT; Yau, HJ | 1 |
| Inada, K; Ishigooka, J; Kasai, A; Miyagi, J; Oshibuchi, H | 1 |
| Ago, Y; Hara, Y; Hashimoto, H; Higashino, K; Katashiba, K; Matsuda, T; Takano, E; Takuma, K; Taruta, A | 1 |
| Chu, Z; Dang, YH; Liang, XP; Liu, P; Xing, B; Zhao, Y | 1 |
| Fu, L; Li, SQ; Pei, W; Yu, Y | 1 |
2 review(s) available for methamphetamine and valproic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antidepressant drug therapy for bulimia: current status.
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Feeding and Eating Disorders; Fenfluramine; Humans; Hyperphagia; Lithium; Lithium Carbonate; Methamphetamine; Monoamine Oxidase Inhibitors; Nomifensine; Phenytoin; Placebos; Propiophenones; Valproic Acid | 1986 |
1 trial(s) available for methamphetamine and valproic acid
| Article | Year |
|---|---|
Antidepressant drug therapy for bulimia: current status.
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Feeding and Eating Disorders; Fenfluramine; Humans; Hyperphagia; Lithium; Lithium Carbonate; Methamphetamine; Monoamine Oxidase Inhibitors; Nomifensine; Phenytoin; Placebos; Propiophenones; Valproic Acid | 1986 |
16 other study(ies) available for methamphetamine and valproic acid
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Distinct features of seizures induced by cocaine and amphetamine analogs.
Topics: Animals; Central Nervous System Agents; Central Nervous System Stimulants; Diazepam; Dose-Response Relationship, Drug; Flunarizine; Hallucinogens; Male; Methamphetamine; Mice; N-Methyl-3,4-methylenedioxyamphetamine; Oxazoles; Rats; Rats, Sprague-Dawley; Seizures; Time Factors; Valproic Acid | 1999 |
Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach.
Topics: Animals; Antimanic Agents; Bayes Theorem; Bipolar Disorder; Brain; Central Nervous System Stimulants; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Enkephalins; Gene Expression Profiling; Genetic Linkage; Genetic Predisposition to Disease; Genetic Testing; Genomics; Humans; Male; Methamphetamine; Mice; Mice, Inbred C57BL; Microarray Analysis; Nerve Tissue Proteins; Pharmacogenetics; Phosphoproteins; Protein Precursors; Substance P; Tachykinins; Valproic Acid | 2004 |
Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice.
Topics: Analysis of Variance; Animals; Anticonvulsants; Cocaine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Inhibition, Psychological; Male; Methamphetamine; Mice; Motor Activity; Valproic Acid | 2005 |
Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine.
Topics: Animals; Anticonvulsants; Behavior, Animal; Central Nervous System Stimulants; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Glutamic Acid; Locomotion; Male; Methamphetamine; Microdialysis; Neuronal Plasticity; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Time Factors; Valproic Acid | 2006 |
Valproate and acetyl-L-carnitine prevent methamphetamine-induced behavioral sensitization in mice.
Topics: Acetylcarnitine; Analysis of Variance; Animals; Behavior, Animal; Drug Administration Schedule; Drug Interactions; Male; Methamphetamine; Mice; Motor Activity; Neuroprotective Agents; Psychomotor Disorders; Time Factors; Valproic Acid | 2007 |
Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage.
Topics: Aldehydes; Analysis of Variance; Animals; Antimanic Agents; bcl-2-Associated X Protein; Brain; Cell Line, Tumor; Central Nervous System Stimulants; Cytochromes c; Dose-Response Relationship, Drug; Drug Interactions; Electron Transport Complex IV; Gene Expression Regulation; Humans; Lithium; Male; Methamphetamine; Mitochondria; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Organic Chemicals; Oxygen Consumption; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Rats; Rats, Inbred WKY; RNA, Small Interfering; Time Factors; Transfection; Tyrosine 3-Monooxygenase; Valproic Acid | 2009 |
Effects of lithium and valproate on oxidative stress and behavioral changes induced by administration of m-AMPH.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Lithium Compounds; Male; Methamphetamine; Motor Activity; Oxidative Stress; Protein Carbonylation; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Valproic Acid | 2012 |
Lithium and valproate modulate energy metabolism in an animal model of mania induced by methamphetamine.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain; Citric Acid Cycle; Creatine Kinase; Disease Models, Animal; Electron Transport Chain Complex Proteins; Energy Metabolism; Lithium Compounds; Male; Methamphetamine; Motor Activity; Rats; Rats, Wistar; Valproic Acid | 2013 |
Methamphetamine downregulates striatal glutamate receptors via diverse epigenetic mechanisms.
Topics: Acetylation; Animals; Corpus Striatum; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Epigenesis, Genetic; Histone Deacetylase 1; Histone Deacetylase 2; Histones; Male; Methamphetamine; Neurons; Rats; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Repressor Proteins; Sirtuin 1; Sirtuin 2; Valproic Acid | 2014 |
Valproic acid inhibits excess dopamine release in response to a fear-conditioned stimulus in the basolateral complex of the amygdala of methamphetamine-sensitized rats.
Topics: Amygdala; Animals; Conditioning, Psychological; Dopamine; Fear; Male; Methamphetamine; Rats; Rats, Sprague-Dawley; Time Factors; Valproic Acid | 2014 |
Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model.
Topics: Animals; Autistic Disorder; Biogenic Monoamines; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Male; Methamphetamine; Mice; Mice, Inbred ICR; Motor Activity; Prefrontal Cortex; Pregnancy; Prenatal Exposure Delayed Effects; Proto-Oncogene Proteins c-fos; Receptors, Dopamine; Valproic Acid | 2015 |
Valproate Inhibits Methamphetamine Induced Hyperactivity via Glycogen Synthase Kinase 3β Signaling in the Nucleus Accumbens Core.
Topics: Animals; Behavior, Animal; Central Nervous System Stimulants; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperkinesis; Male; Methamphetamine; Microinjections; Motor Activity; Nucleus Accumbens; Phosphorylation; Rats; Rats, Sprague-Dawley; Serine; Signal Transduction; Valproic Acid | 2015 |
Brain transcriptomics of nonhuman primates: A review.
Topics: Aging; Animals; Brain; Brain Diseases; Disease Models, Animal; Ethanol; Humans; Methamphetamine; Neurosciences; Primates; RNA-Seq; Sevoflurane; Transcriptome; Valproic Acid | 2021 |